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In 1999, ovarian cancer was the eighth commonest 
cancer and the sixth most common cause of death 
from cancer in Australian women (Table 1).1 This in 
no small way reflects the late presentation for the 
majority of women.
Symptomatology
Epithelial ovarian cancers tend to occur most commonly 
in the peri- and post-menopausal woman. Symptoms 
are usually vague – accounting for the late presentation 
– and may include:
• pressure symptoms – bladder, bowel
• increased abdominal girth
• fatigue
• gastrointestinal symptoms – indigestion or lack of 
appetite, change in bowel habits, constipation, or
• less commonly, pain.
Vine et al3 reported that 92% of women with invasive 
ovarian tumours and 84% of borderline cases have 
symptoms with a median duration of 4 months.
 Obviously not all peri- or post-menopausal women 
with these symptoms will have ovarian cancer, but 
symptoms which persist (eg. for 1 month) should be 
investigated. The question should always be raised: 
‘Could this be ovarian cancer?’
 The thought that a woman may have a psychosomatic 
problem should not overrule clinical suspicion of 
malignancy in women with persistent symptoms. A 
high level of suspicion is a useful adjunct in making the 
diagnosis of ovarian cancer particularly:
• in women with a family history of ovarian cancer
• women over 45 years of age, or 
• where symptoms appear to persist in the absence 
of any alternative explanation.
Investigation
Clinical examination, including a pelvic examination may 
reveal:
• increased girth either ascites, or
• an abdominal mass (omental cake), and/or
• pelvic mass – filling the pouch of Douglas (best felt 
by recto-vaginal examination).
Depending on f indings and symptomatology, a 
transvaginal ultrasound or computerised tomography 
(CT) scan of the abdomen and pelvis may confirm any 
physical findings.
 Gastrointestinal symptoms may frequently lead to 
a referral for endoscopy – which will be negative. Both 
the general practitioner and the endoscopist need to 
consider ovarian cancer in these cases where symptoms 
persist and are not explained.
 Tumour markers (CA-125) may be elevated (see the 





Epithelial ovarian cancer presents most often as late stage disease due to a lack of effective screening tests and 
vagueness of symptoms.
OBJECTIVE
This article outlines the diagnosis and management of ovarian cancer.
DISCUSSION 
Women with suspected ovarian cancer are best managed in a gynaecological treatment unit offering multidisciplinary 
care. Surgery is usually needed both to make a diagnosis and for definitive treatment and referral to a specialty trained 
gynaecological oncologist is appropriate. Most women will also require chemotherapy. Ovarian cancers have good 
sensitivity to several drugs but relapse rates are high. This means that ovarian cancer is now seen as a chronic disease 
with often several episodes of remission, relapse and treatment. The psychological impact of this diagnosis both on the 
woman and her family are significant and best dealt with proactively.
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Diagnosis
The definitive diagnosis is made surgically. Where 
suspicion is high, surgery is best performed by a 
gynaecological oncologist with training in all aspects in the 
management of ovarian cancer. At this surgery, staging is 
also undertaken as well as definitive treatment.4
 A total abdominal hysterectomy, bilateral salpingo-
oophorectomy, omentectomy, examination of pelvic 
and para-aortic lymph nodes, as well as a careful search 
throughout the peritoneal cavity to detect and remove 
any tumour deposits will be undertaken. Occasionally 
where tumour affects the bowel, bowel resection, usually 
with primary reanastomosis, may also be necessary.
 The aim of the surgery therefore, is to remove all 
tumour deposits as much as possible to leave no or 
minimal tumour burden remaining. The stage of the 
tumour is therefore determined at this surgery and gives 
a guide to prognosis. The stage of the tumour acts as a 
guide to further management (Table 2).
What is ‘standard management’?
Ideally each woman should be managed in the setting 
of a multidisciplinary team, where each member has 
expertise in ovarian cancer care specifically, as well as 
their own field. There is evidence that outcomes for 
women in this setting are maximised.5,6
 With exception of certain women whose disease 
is still stage I, the majority of women will expect to be 
offered chemotherapy after surgery. The gold standard 
currently is paclitaxel and carboplatin combination.7 The 
standard dose of paclitaxel of 175 mg/m2 and carboplatin 
AUC x 6 given every 3 weeks is generally well tolerated.8 
This is given usually in a day centre one day every 
21 days for six cycles. Blood tests to ensure bone 
marrow recovery before each cycle are undertaken. A 
consultation also occurs before each cycle to investigate 
the efficacy of the treatment as well as management 
of any side effects from chemotherapy. Tumours have a 
good sensitivity to these drugs and about three-quarters 
may expect a positive response.
 Chemotherapy usual ly  commences as soon 
as practical after surgery when bowel function 
has recovered. There is no advantage in delaying 
chemotherapy because of wound healing. There is also 
no evidence to suggest that more than six cycles of 
chemotherapy offer any further advantage.
 As well as monitoring bone marrow function the 
tumour marker CA-125 can be used as an additional 
means of assessing response. CA-125 has a half life of 
approximately 6 days. Provided the CA-125 continues to 
fall, treatment should continue to maximum of six cycles.
Follow up after primary treatment
Present evidence does not support the use of any 
maintenance or consolidation therapy after initial 
treatment.9 CA-125 is also used to monitor for tumour 
relapse. A rise to more than twice the upper limit of normal 
during follow up accurately predicts tumour relapse.10
 Despite the relatively high response to chemotherapy, 
the majority of advanced ovarian cancer patients will 
relapse. The interval between the end of first line therapy 
and relapse (the so-called ‘treatment free interval’) is of 
prognostic significance. The longer the treatment free 
interval, the higher the likelihood of a further worthwhile 
response.11 Experience would suggest that a treatment 
free interval greater than 12 months is associated with 
a significant number of patients deriving worthwhile 
benefit from re-treatment. Women whose disease recurs 
in less than 6 months (platinum refractory) usually do 
not respond to other forms of therapy. In all cases of 
second line therapy, it is important to monitor patients 
carefully and only continue treatment if there is objective 
evidence of response. It is essential that the quality of 
life of the woman is a major part of assessment.
Radiation therapy
Following surgery, chemotherapy has been the major 
thrust of treatment, however, radiation therapy has 
been useful in some women. The systematic study of 
radiation therapy has been hampered by poor accrual to 
large randomised trials.  Whole Abdominal Radiotherapy 
(WART) has been used in patients with stage I, II and 
III disease with no macroscopic disease in the upper 
abdomen after completion of surgery.12 The amount 
of radiation delivered to the abdomen is limited by the 
normal organs in the field. The dose is limited to 45–50 
Gy in relatively low fractions of up to two Gy per fraction. 
Most patients experience acute side effects including 
nausea, vomiting and diarrhoea. Myelosuppression has 
been a common reason for treatment interruptions. 
Up to 10% of patients do not complete therapy. The 
late complications of WART include chronic diarrhoea, 
transient liver enzyme disturbance, basal pneumonitis, 
cystitis and bowel obstruction.
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Common side effects of therapy
Surgery
The common postsurgical problems of infection, 
thrombosis and poor wound healing are similar to any other 
surgery. Postoperative ileus may be higher because of 
bowel involvement with tumour.
Chemotherapy
With the advent of modern antinausea medication, 
nausea and vomiting are usually a thing of the past when 
undergoing chemotherapy. Medication will include a 5HT3 
antagonist and possibly also an anxiolytic. Both paclitaxel 
and platinum can produce peripheral neuropathy and 
women must be warned of this possibility. The neuropathy 
may often not appear until quite late in the cycle of 
chemotherapy or even after it is completed. Paclitaxel can 
also cause muscle and joint pain that may last from a few 
hours to several days in the first week after therapy.
 Bone marrow suppression may occur. Carboplatin may 
be more responsible for platelet depletion whereas both 
drugs equally will affect neutrophils.
Prognosis
The majority of patients will present with stage III or 
IV disease (about 75%). While the response rates to 
primary chemotherapy with paclitaxel and carboplatin 
are relatively high, the majority of women will eventually 
relapse and succumb to their disease. Survival rates are 
in the order of 40%.
Quality of life
Ovarian cancer should be seen as a chronic disease 
with often several episodes of remission, relapse and 
treatment. It is essential that the quality of life of women 
with ovarian cancer is a major part of assessment and 
consideration of quality of life issues underpin any 
treatment decisions.
 There is Level one evidence that psychosocial 
intervention can result in lower rates of anxiety and 
depression, and nausea and vomiting for patients with 
cancer.13 Psychosocial interventions can include counselling 
and relaxation therapy, education programs to improve pain 
control, and cognitive behavioural interventions, all of which 
have shown positive benefits.
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Conclusion
In women with epithelial ovarian cancers symptoms 
are usually vague and as a consequence presentation 
and/or diagnosis is often late. A high level of suspicion 
is important in making the diagnosis of ovarian cancer 
particularly in the peri- and post-menopausal woman, 
those with a family history of ovarian cancer, and when 
symptoms persist for more than 1 month. Women 
with suspected ovarian cancer are best managed in a 
gynaecological treatment unit offering multidisciplinary 
care. Surgery is usually needed both to make a diagnosis 
and for definitive treatment. Most women will also require 
chemotherapy. Ovarian cancers have good sensitivity to 
several drugs but relapse rates are high.
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